144 related articles for article (PubMed ID: 15389784)
21. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy.
Selander KS; Li L; Watson L; Merrell M; Dahmen H; Heinrich PC; Müller-Newen G; Harris KW
Cancer Res; 2004 Oct; 64(19):6924-33. PubMed ID: 15466183
[TBL] [Abstract][Full Text] [Related]
22. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130.
Howlett M; Judd LM; Jenkins B; La Gruta NL; Grail D; Ernst M; Giraud AS
Gastroenterology; 2005 Sep; 129(3):1005-18. PubMed ID: 16143138
[TBL] [Abstract][Full Text] [Related]
23. Establishment of a highly tumorigenic LNCaP cell line having inflammatory cytokine resistance.
Kawada M; Inoue H; Usami I; Takamoto K; Masuda T; Yamazaki Y; Ikeda D
Cancer Lett; 2006 Oct; 242(1):46-52. PubMed ID: 16377078
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study.
Hirano D; Jike T; Okada Y; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Yoshida T; Takimoto Y
Ultrastruct Pathol; 2005; 29(5):367-75. PubMed ID: 16257863
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Am J Pathol; 1999 Feb; 154(2):543-51. PubMed ID: 10027412
[TBL] [Abstract][Full Text] [Related]
27. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2.
Diaz M; Abdul M; Hoosein N
Prostate Suppl; 1998; 8():32-6. PubMed ID: 9690661
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation.
Wang Q; Horiatis D; Pinski J
Prostate; 2004 Nov; 61(3):253-9. PubMed ID: 15368468
[TBL] [Abstract][Full Text] [Related]
30. Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells.
Untergasser G; Plas E; Pfister G; Heinrich E; Berger P
Prostate; 2005 Sep; 64(4):419-29. PubMed ID: 15800938
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
32. Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer.
Wu C; Zhang L; Bourne PA; Reeder JE; di Sant'Agnese PA; Yao JL; Na Y; Huang J
Prostate; 2006 Aug; 66(11):1125-35. PubMed ID: 16652382
[TBL] [Abstract][Full Text] [Related]
33. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract][Full Text] [Related]
34. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.
You Z; Shi XB; DuRaine G; Haudenschild D; Tepper CG; Lo SH; Gandour-Edwards R; de Vere White RW; Reddi AH
Cancer Res; 2006 Jan; 66(1):175-83. PubMed ID: 16397230
[TBL] [Abstract][Full Text] [Related]
36. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
37. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
38. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.
Palapattu GS; Wu C; Silvers CR; Martin HB; Williams K; Salamone L; Bushnell T; Huang LS; Yang Q; Huang J
Prostate; 2009 May; 69(7):787-98. PubMed ID: 19189306
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
